Mission: Ongoing! China Looks To Align With FDA In Landmark IND Push
Issuing new guidance for INDs, doubling reviewers, adopting priority and accelerated reviews, and cutting a submission backlog are among the raft of measures the China FDA is quietly but assertively taking to accelerate new drug approvals and support innovation.
You may also be interested in...
Amid aftermath of latest vaccine scandal, top officials including China’s drug reform flagbearer are forced to resign, sending shock waves across the industry.
Allowing early stage Phase I studies, setting a 60-day period for IND approvals, and dropping a requirement for hospital to get certified, the China FDA proposes fundamental changes that would allow any qualified sites to file for approval to get studies rolling.
Although Chinese President Xi Jinping has expressed the country's willingness to work with the newly elected US president to promote ties in a constructive way, potential setbacks for bilateral trade and regulatory talks are worrying observers.